Scarica l'app Stockscreener
27.64
19.18%
-6.56
Dopo l'orario di chiusura:
28.18
0.54
+1.95%
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million - Investing.com
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Nigeria
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares - MarketBeat
Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144 - Stock Titan
Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS - MarketBeat
Cue Biopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cue Biopharma Q2 Results: EPS Loss Widens to $24.14 Despite Sales Beat - scanx.trade
Is Cue Biopharma Inc (CUE) Facing Financial Strain After Q2 Loss - GuruFocus
Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges - TradingView
Cue Biopharma Raises $50M for CUE-221 Food Allergy Program - Stock Titan
Cue Biopharma Stock (CUE) Opinions on Management Changes and Phase 2 Data Prospects - Quiver Quantitative
Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G - Stock Titan
Cue Biopharma Inc. (NASDAQ: CUE)Dividends - intelligentinvestor.com.au
Cue Biopharma, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Cue Biopharma (CUE) registers 1.51M shares for stockholder resale after $50M raise - Stock Titan
Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday - MarketBeat
Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%Should You Sell? - MarketBeat
Cue Biopharma (CUE) Holds Steady Near $27 as Biotech Sector Digests MomentumEMA Signal - dars.gov.et
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc. expected to post a loss of $1.69 a shareEarnings Preview - TradingView
Cue Biopharma Inc (CUE) Stock News Today - TradingKey
Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cue Biopharma Appoints Veteran James Ahlers as CFO - The Globe and Mail
Cue Biopharma Appoints James Ahlers as Chief Financial Officer – SEC 8-K Filing Details - Minichart
Cue appoints James Ahlers as Chief Financial Officer - TradingView
Cue Biopharma (CUE) hires James Ahlers as CFO with equity and severance package - Stock Titan
Cue Biopharma, Inc. Announces Appointment of James Ahlers as Principal Financial Officer, Effective July 30, 2026 - marketscreener.com
Cue Biopharma names James Ahlers as chief financial officer By Investing.com - Investing.com Nigeria
Cue Biopharma Names James Ahlers CFO - Moomoo
Cue Biopharma names James Ahlers as chief financial officer - Investing.com
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - Yahoo Finance
Cue Biopharma appoints James M. Ahlers as CFO to steer clinical-stage growth - scanx.trade
Cue Biopharma Inc (CUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CUE|Cue Biopharma Inc|Price:32.120|Chg%:-0.970 - TradingKey
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Company Profile & Introduction - Moomoo
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
Cue Biopharma Inc (CUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cue Biopharma Inc (CUE) Income Statement - TradingKey
Cue Biopharma Inc (CUE) Balance Sheet - TradingKey
Cue Biopharma, Inc. Revenue Breakdown – NASDAQ:CUE - TradingView
Cue Biopharma Inc (CUE) Cash Flow - TradingKey
Cue Biopharma Inc (CUE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – DUS:1UC0 - TradingView
Cue Biopharma (CUE) Stock Forecast & Analyst Ratings - Moomoo
Cue Biopharma, Inc. announced that it has received $49.999926 million in funding from Cormorant Asset Management, LP, Threadneedle Asset Management Limited - marketscreener.com
Cue Biopharma (CUE) completes $49,999,927 Reg D Rule 506(b) raise - Stock Titan
ETFs Investing in Cue Biopharma, Inc. Stocks - TradingView
Cue Biopharma (CUE) Q2 2024 earnings summary - Quartr
Cue Biopharma (NASDAQ:CUE) Stock Price Down 0.7%Here's Why - MarketBeat
Form 4 Cue Biopharma For: 15 July By Investing.com - Investing.com Nigeria
Cue Biopharma (CUE) awards RSUs and stock options to CMO Borie - Stock Titan
Cue Biopharma (NASDAQ: CUE) CMO Dominique Borie files initial Form 3 - Stock Titan
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):